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A B S T R A C T
Purpose: Controlled randomized studies recommending the clinical use of lamotrigine in adult
populations with the diagnosis of Juvenile Myoclonic Epilepsy are still lacking. To compare the efﬁcacy
and tolerability of lamotrigine versus valproate in adult patients with JME.
Methods: This was a prospective, randomized, controlled, pragmatic, long-term and open-label
treatment trial. Patients were randomized to use valproate or lamotrigine. The primary end points of
the study were: (1) time from randomization to treatment failure (withdrawal); (2) time from
randomization to seizures remission. Secondary ending points were: (1) frequency of clinically
important adverse events and (2) change in the QOLIE-31 after randomization. The deﬁnition of seizure
remission was based on disappearance of all seizure types and EEG discharges.
Results: We found that the time to withdraw treatment after randomization was not signiﬁcantly
different in lamotrigine and valproate groups. Long-term seizures freedom was equal in the both groups
of the trial; only 8 (19.1%) patients randomized to lamotrigine and 6 (19.4%) randomized to valproate
were not seizure free after 4 months of treatment. Between 17.03% (lamotrigine) and 35.3% (valproate) of
patients reported adverse reactions at some point in the intention-to treat study (p = 0.07). All subscales
of the QOLIE-31 questionnaire, except that related to side effects of medication, improved more than 5
points with respect to baseline period in both groups
Conclusion: Lamotrigine is effective in adult patients with Juvenile Myoclonic Epilepsy and better
tolerated than valproate, although the incidence of idiosyncratic reactions could be a cause of concern.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Juvenile Myoclonic Epilepsy (JME) represents the most
common form of idiopathic generalized epilepsy (IGE).1
JME seizures respond well to antiepileptic drugs (AEDs),
particularly valproate. The SANAD (Standard and New Antiepilep-
tic Drugs) study reported that valproate was the most effective and
best-tolerated ﬁrst-line AED for patients with IGE, including JME,
when it was compared to lamotrigine and topiramate (TPM).2
Valproate is the ﬁrst-line drug in men with JME, but in female
population, lamotrigine (LTG) is preferred due to the teratogenic
and endocrinologic side effects such as polycystic ovary syndrome
and weight-gain associated to valproate. Recent data suggest that* Corresponding author at: 29 y D vedado, Plaza, La Habana, Cuba.
Tel.: +53 8345575.
E-mail addresses: renemachado@infomed.sld.cu, reneandrade1970@yahoo.es
(R.A. Machado).
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http://dx.doi.org/10.1016/j.seizure.2013.07.006it may soon be used as ﬁrst line treatment2–5; nevertheless, some
studies have reported aggravation of JME with LTG.6–12
LTG is a phenyltriazine derivative which acts through inhibition
of voltage-activated sodium channels and possibly calcium
channels, preventing the release of glutamate.5 LTG is effective
in controlling generalized tonic–clonic seizures (GTCS) and
absence seizures13–17; while there are some reports of myoclonic
seizure exacerbation.6,7 Nevertheless, many studies performed
over the recent years have demonstrated the clinical utility of this
AED for the treatment of JME.6–9
Demonstration of LTG’s usefulness in JME is especially
important for women who live in developing countries, due to
the lack of levetiracetam, zonisamide and TPM18–20 and also for
those female or male patients who have had adverse reactions to
valproate or who have contraindications for its use.
That’s why, in some scenarios, LTG has become the ﬁrst line AED
in women with JME of childbearing potential and even in men.
Nevertheless, to our knowledge, open labeled, prospective,
controlled randomized trials, that allow recommendation of LTG
for adult population with JME in clinical practice, are still lacking.vier Ltd. All rights reserved.
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tolerability of lamotrigine in adult patients with JME.
2. Methods
2.1. Study design
This was a prospective, randomized, controlled, pragmatic,
long-term, open-labeled treatment trial. The study was carried out
at the National Institute of Neurology and Neurosurgery in Havana,
Cuba.
2.2. Study population
Patients from the whole country are referred to our institution
which is a tertiary center. The epilepsy section offers medical
assistance to 1089 patients with epilepsy. Juvenile Myoclonic
Epilepsy represents approximately 10.3% of all epileptic syn-
dromes treated in our institution.
2.3. Diagnosing process and follow-up
All subjects were enrolled in the study sequentially from the
outpatient clinic. The ﬁrst patient was included on January 2nd
2008, and randomization continued up to June 30th 2010.
Attempts were made to follow all patients for at least 2 years,
but those who did not return to the outpatient clinic, wereFig. 1. Trail proﬁle. The total number of patients that withdrew from treatment for any rea
between two proportions), p = 0.02.included in until the moment they were evaluated for the last time
(ITT protocol). Trial design can be seen in Fig. 1.
All patients and two of their relatives were interviewed by
experienced epileptologists concerning seizure types, age at
seizure onset, seizure precipitant factors, possible circadian
rhythm of seizures and previously used medications.
In all the patients where Juvenile Myoclonic Epilepsy was
suspected, a routine 21-channel EEG was obtained, according to
the international 10–20 system employing a Medicid EEG digital
machine, at the moment of entering the study and after 2 years of
follow-up. All patients were sleep deprived the night before to EEG
performance. At least 10 min of sleep were recorded in each
patient, which primarily resulted in early sleep stages recording
(stages 1 and 2 of non-REM sleep) and only rarely stage 3 non-REM
sleep was seen. EEG recordings had a mean duration of
approximately 30 min.
Taking into account seizure semiology and the electrographic
pattern obtained, the diagnosis of JME was made by two
epileptologists according to the ILAE criteria.13 Seventy-two
patients (100%) had myoclonic seizures, 45 patients had GTCS
(62.5%) and absence seizures were reported in only 27 (37.5%).
2.4. Inclusion criteria
Patients were included in the study if they had past history of
two or more generalized myoclonic seizures. Tonic–clonic or
absence seizures in the previous years were also taken intoson was 12/31 in the valproate group and 6/41 in the lamotrigine group (differences
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diagnosis, all enrolled patients had a past history of this seizure
type. However, subjects without absences or tonic–clonic seizures
were also included in the study. These criteria allowed inclusion of
patients with newly diagnosed epilepsy and patients who had been
previously treated under monotherapy or politherapy regimens (as
long as the treatment failure was not due to one of the drugs
employed in the trial).
2.5. Exclusion criteria
Patients with insufﬁcient documentation of seizure frequency,
poor compliance, progressive neurological diseases, severe psy-
chiatric disorders, drug or alcohol abuse, systemic disorders,
laboratory abnormalities or those who were pregnant or breast-
feeding, were not eligible for the study.
2.6. Follow-up
Those patients who were taking at enrolment antiepileptic
drugs that worsen Juvenile Myoclonic Epilepsy, such as carbamaz-
epine or phenytoin, were instructed to drop the doses out slowly
during the following 3 weeks and afterwards, they should return to
the outpatient clinic to start with valproate or LTG.
After the diagnosis was conﬁrmed, they were interrogated
concerning the number of seizures in the last 2 months (baseline
period). All seizure types were scored: myoclonic, absences or
GTCS. An information booklet describing the seizure types was
given to all patients and their relatives in order to obtain an
adequate score. The booklet summarized the following informa-
tion:
- Myoclonic seizures are considered as shock-like movements,
irregular and arrhythmic sudden contractions of proximal and
distal muscles, mainly of the upper extremities; sudden
involuntary movements making the patient prone to drop things
or look clumsy.
- Absence seizures should be described by a relative or a witness.
Absences are characterized by sudden onset and interruption of
ongoing activities, blank stares, slowing or speech interruption;
standing transﬁxed and unresponsive when spoken to. Addition-
ally, as the patient may not stop his or her activities, absences
seizures are considered if the relative is aware of slowing down of
speech.
- GTCS are considered as convulsions.
As the patients were prospectively studied, baseline seizure
rate was estimated from patient’s memories at study entrance; but
subsequent seizure rate was calculated from seizure diaries. No
statistical analyses were made to compare the number of seizures
per month before and after treatment. The past history of seizures
was used only to train patients and relatives on the semiology of
different seizure types.
The epileptologists randomized patients with a computer
program using a minimization procedure. Three patients were
not eligible and 4 did not sign the informed consent.Table 1
Guideline for titration of medications during follow-up.
Medication
(dose/weeks) Valproate
Week Week Week 
1–2 3–4 5–6 
Medication (dose/weeks) 200 mg/3 times/day 400 mg/3 times/day 600 mg/3 tim
Week Week Week 
Lamotrigine 1–3 4–7 8–11 
25 mg single dose 25 mg/times/day 50 mg/2 timeParticipating patients (eligible) were randomly allocated to
valproate (n = 39) or LTG (n = 43). Before initiating treatment,
the epileptologists explained the possible side effects of each
medication. Then, patients were instructed to pick up the
medication every month at the hospital pharmacy. A pharma-
cologist gave the patients all the pills every month without any
cost. Eight patients randomized to Valproate regimen and 2
patients randomized to the LTG group were not treated, and
were dropped out of the study because they did not pick up their
medication. Those patients, who were not included in the study,
were followed in the corresponding secondary centers. Thus, the
total number of patients assigned to LTG was higher than the
number of patients in the valproate group, in spite of having
been correctly randomized. Finally, 31 patients were in the
valproate arm and 41 in the LTG arm.
Data from patients who withdrew from the study for any cause
were included in the analyses up to the moment of their last
follow-up visit.
Although the prescribed drug was determined by randomiza-
tion, drug dose was that prescribed by the physicians in their
everyday practice. The initial maintenance dose, and any subse-
quent increment or decrement was decided by the epileptologists,
but the rate of titration was aided by guidelines (Table 1). The
mean doses of each drug at the end of the study and at withdrawal
are showed on the right inferior part of Fig. 1.
The aim of treatment was to control seizures with the minimum
effective dose of the drug. Visits were scheduled approximately once
per month. Additional visits were allowed according to patients’ or
families’ needs. The doses of the AED were increased in those
patients in whom new seizures appeared (as is usual in clinical
practice). In those cases, dose increments consisted of 200 mg for the
valproate group and 50 mg for the lamotrigine group.
Therapy failure was considered when intolerable side effects or
ongoing seizures occurred, in spite of an adequate dose, and if the
patients could not be followed during 3 months. All of those
patients were dropped out from the study.
Due to the fact that we could not measure plasma concentration
of AEDs, to consider therapy failure of lamotrigine or valproate, the
dose should be titrated to the maximum orally tolerated doses
when it was necessary. Those patients with treatment failure
continued their follow-up in our outpatient clinic and they were
crossed-over to valproate if they were under treatment with
lamotrigine and to lamotrigine if they were under treatment with
valproate (the results of the crossover trial will not be described in
the present study).
To determine seizure rate, all seizures written in the patient’s
diaries were recorded by the epileptologists in every visit. Only
episodes with semiologic characteristics compatible with absence,
myoclonic or GTCS were registered and considered for the
statistical analysis. Thus, episodes different to these seizure types
were ruled out and not analyzed.
2.7. Evaluation of efﬁcacy
The primary end points of the study were: (1) time from
randomization to treatment withdrawal (stopping the randomizedWeek Week Week Week
7–8 9–10 11–12 13–14
es/day 2000 mg daily 3000 mg daily 3000 mg daily 3000 mg/Daily
Week Week Week Week
12–15 16–19 20–24 25–27
s/day 50 mg/3 times/day 100 mg/times/day 250 mg/daily 300 mg/daily
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effects, or both; whichever was the earliest) and (2) time from
randomization to seizure remission. Secondary end points of the
study were: (1) frequency of clinically important adverse events
and side-effects emerging after randomization, (2) quality of life
outcomes, (3) number of seizures evaluated at 3, 6 and 24 months
after treatment was initiated.
2.8. Seizure outcome assessment
Seizure outcome was assessed through clinical visits. The
baseline seizure rate was considered as seizure frequency at 2
months before enrolment. For each patient the number of
myoclonic, absence and GTCS per month during follow-up was
calculated taking into account seizure diaries.
Only patients who reported having no seizures and with normal
EEG recordings at the end of the study (2 years after study
entrance), were considered to be seizure free.
Normal EEG at the end of the research was considered in those
cases with EEG recordings obtained after 6 h of sleep deprivation,
during 30 min, in which normal background activity with total
absence of generalized polyspikes and spikes and waves and
photoparoxysmal activity were reported.
Inadequate seizure control was considered in those patients
who continued with some seizure types in spite of adequate dose
regimens and treatment compliance. Because measurement of
drug plasma levels was not feasible, an adequate dose regimen was
operationally considered when maximal tolerated dose was
reached or when more than 2000 mg/day in the valproate group
or more than 300 mg/day in the LTG arm was achieved.
2.9. Quality-of-life assessment
All patients who were cognitively able to give informed consent
and who could complete a quality-of-life inventory received the
QOLIE-31 questionnaire within the 4 weeks previous to randomi-
zation. The Quality of Life questionnaire (QOLIE-31) consists of a
31-item scale that assesses seizure worry, well-being, energy or
fatigability, social functioning, cognitive functioning, side effects of
medication and overall quality of life.14 The scoring scale extends
from 0 to 100, with the highest score reﬂecting the best quality of
life.14 The questionnaire was administered when the patients were
enrolled in the study and after 2 years of follow-up.
2.10. Adverse events assessment
In each visit the patients and their relatives were requested to
report any symptom felt after drug treatment was initiated. If so,
adverse event was considered if the referred symptom had been
previously described for valproate of for LTG. In case symptoms
had not been described for the medication under analysis, they
were taken into account if no other explanation was found.
2.11. Compliance assessment
Treatment compliance was assessed on the basis of returned
tablet counts, and it was deﬁned as tablet consumption within 80–
120% of the prescribed dose.
2.12. Ethics
The study was conducted according to the Declaration of
Helsinki’s criteria and no funding was received from pharmaceu-
tical companies. The patients gave their informed consent to
participate in the study, which was approved by the local ethics
committees.All authors had full access to the data and took responsibility for
its integrity and for the accuracy of the data analysis. The
corresponding author had the ﬁnal responsibility for the decision
to submit for publication.
2.13. Statistical analysis
We decided to assess whether treatment with LTG had
advantages in tolerability and safety, or even if there were no
immediate advantage, if it could be an alternative or second-line
therapy (test of equivalence). Due to the above mentioned design,
instead of the conventional test of signiﬁcance, statistical analysis
is based on conﬁdence intervals (CIs) that deﬁne a range for the
possible true differences between the treatment groups. Taking
this paradigm into account, the two studied drugs were considered
as equivalent if the entire CI for their difference lies within the pre-
set clinically relevant range of equivalence.
Pre-set clinically relevant range of equivalence: taking into
account that valproate is the ﬁrst eligible drug to treat patients
with JME and its proved efﬁcacy in this epileptic syndrome, the
number of seizures evaluated at 3, 6 and 24 months after treatment
was initiated, should not be statistically different between
randomized groups in terms of CI.
The statistical analysis included intention to treat analysis (ITT)
and per protocol analysis (PPA). Intention to treat analysis
considered all patients who received at least one drug dose. For
patients who dropped out from the study the analysis included all
available data until patients withdrew from the study; whereas per
protocol analysis included only those patients who ﬁnished the
follow-up.
2.14. Primary end point
The time from randomization to treatment withdrawal
(stopping the drug the patient was randomized to because of
inadequate seizure control, intolerable side-effects, or both;
whichever was the earliest) (ITT) and the time from randomization
to seizure remission (PPA) were analyzed using the Kaplan Meier
method, comparing the mean time with each seizure type during
the follow-up period.
To analyze the secondary ending point, ANOVA (Wilk Lamda)
and T tests were used to compare continuous variables. Mann–
Whitney was used to compare discontinuous variables. Qualitative
variables were compared using the Chi square test. Side-effects of
medication were analyzed comparing the proportion of patients
who reported/experienced side effects. To evaluate the differences
between rates of adverse events and proportions of patients who
dropped-out from the study in both randomized groups, we tested
the difference between proportions. This was computed according
to the following formula:
=t value= ¼ squareðN1  N2Þ=ðN1 þ N2Þ  = p1  p2=square½ p
 q where q
¼ 1  p and p ¼ ð p1  N1 þ p2  N2Þ=ðN1 þ N2Þ:
For all measurements only p values below 0.05 were considered
signiﬁcant.
3. Results
3.1. Demographic, clinical and electrographic results
Forty-one patients were randomized to the lamotrigine group
and 31 to the valproate arm. Twenty-ﬁve (30.5%) out of 82 patients
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(mean doses 970  230 mg/daily). Thirty-eight (46.3%) had been
treated with carbamazepine associated with clonazepam and they
reported total control of their GTCS, although myoclonic seizures had
continued (mean doses 670  135 mg/daily vs. 1.1  0.3 mg/daily).
Two patients (2.4%) had received phenytoin but they had discon-
tinued the medication as they noticed seizure worsening (mean doses
150  50 mg/daily). Seventeen patients (20.7%) had never received
any medication before.
Patients were aged between the second and ﬁfth decade of life
at study entrance. The predominant seizure type in both groups
was myoclonic jerks. Both groups of patients had a history of
convulsions for more than 10 years. In all patients the interictal
electrographic patterns were characterized by the presence of
generalized polyspikes, and spikes and waves; although focal
paroxysmal activity was documented in approximately 19%. Thus,
treatment groups were well balanced for demographic, clinical and
electrographic factors (Table 2). There was no statistical difference
between male/female rates by groups.
3.2. Follow-up by groups of treatment
As expected, doses associated with treatment failure due to
unacceptable adverse events were consistently lower than doses
associated with treatment failure due to an inadequate seizure
control (Fig. 1, see up-titration scale). In spite of the fact that,
dosing was left to the physician’s usual practice, the total doses of
VPA were similar in each group and they were not lower in the
female group, p > 0.05.
Thirteen cases declined further follow-up during the study
because of unacceptable side effects: 9 in the valproate arm (29%)
and 4 in the lamotrigine arm (9.8%), (p < 0.05). Two out of 4
patients in the LTG arm suffered from Stevens–Johnson Syndrome
(SJS). One of them was a 23-year old female who presented the SJS
3 weeks after the initial doses of LTG. The total daily doses at SJS
presentation was 50 mg/day. The second one was a 25-year old
black male, who presented SJS 5 weeks after the initial doses. Total
daily doses in this case at SJS presentation were 100 mg/day. Both
patients were hospitalized and treated with prednisolone (60 mg/
day for 7 days) and lamotrigine was changed for valproate. Both
were delivered from our hospital after complete resolution of the
syndrome (12 and 11 days after admission, respectively).
Four patients were lost from follow-up for other reasons, and
one patient was dropped out because of inadequate seizure control
in spite of adequate compliance (the patient had been allocated to
the lamotrigine group). The total number of patients that withdrew
from the study for any reason was 12/31 (38.7%) in the valproate
group and 6/41 (14.6%) in the lamotrigine group. Statistical
analysis showed that the percentage of patients who dropped out
was signiﬁcantly higher in the valproate arm (Fig. 1).
3.3. Treatment failure events
To achieve clinical beneﬁt and complete seizure remission in
the responder group, it was unnecessary to reach the maximal
tolerated doses of lamotrigine or valproate in any case (Table 2).Table 2
Incidence of adverse events leading to drug discontinuation during treatment period i
Medication Number of patients with adverse events 
Valproatea 9 (12.5) 
Lamotrigine 4 (5.6) 
Total 13 (18.1) 
Chi-square test (DF = 1) = 4.4, p = 0.03.
a Number of patients with adverse events (comparison between valproate and lamoAnalysis of treatment failure due to unacceptable adverse
events (Table 3) indicates that lamotrigine was less associated
with unacceptable adverse events than valproate (p < 0.05).
Otherwise, lamotrigine was not signiﬁcantly less effective than
valproate for the treatment of myoclonic, absence and tonic–
clonic seizures (see Kaplan Meir survival curve in Fig. 2A–C).
Nevertheless, in one patient randomized to lamotrigine treat-
ment, myoclonic seizures worsened with respect to the starting
point seizure rate (Fig. 1).
The time to treatment withdrawal for any reason was lower
in the valproate group compared to the LTG group, but without
statistical signiﬁcance (Table 4). Total seizures per group of
randomization during follow-up (3, 6 or 24 months) were
equivalent and CIs for seizure frequency during follow-up in the
LTG and valproate groups were similar (Table 4). Three patients
in the valproate group (9.7%) and 4 (9.7%) in the LTG group, did
not reach total control of myoclonic seizures (Table 4).
Seizure remission rates at the end of the follow-up period are
shown in Fig. 3A. A high proportion (more than 80%) of patients
achieved total seizure control after 4 months treatment. The
proportion of patients who remained with seizures after treatment
was not signiﬁcantly different in the LTG and valproate groups
(p > 0.05). Otherwise, 2 patients (4.8%) randomized to the LTG
group still showed polyspikes and spikes and waves in the EEG
after 2 years of treatment, whereas all cases (100%) in the valproate
arm had EEG normalization (p > 0.05) (Table 4).
3.4. Compliance assessment
Two patients (6.5%) in the valproate arm had a total tablet
consumption of approximately 80%, the rest had a tablet
consumption ranging from 90% to 100%. Three patients in the
LTG group (7.3%) had a total tablet consumption of approximately
80%; the rest had 100% compliance (Table 5).
3.5. Adverse events
An intention-to-treat approach summarizes adverse events
associated with the randomized policy. As patients could not have
treatment changes during follow-up, this approach clearly shows
adverse events attributable to speciﬁc drugs. Therefore, in Table 5
we present adverse event rates for both intention to treat and per
protocols. Seven patients (17.03%) in the LTG arm and 11 subjects
(35.3%) in the valproate arm reported adverse events at some point
in the intention-to treat study. This difference reached statistical
signiﬁcance (p = 0.04). Among the individual symptoms, the most
commonly reported were: allergic rash (4 patients; 9.8%) and sleep
disturbances (3 patients; 7.3%) for the LTG arm; and weight gain (5
patients; 16.1%), alopecia (3 patients; 9.7%), dyspepsia (9.7%) and
nausea (9 patients; 29.1%) in the valproate arm. Rash was a
prominent non-central nervous system symptom, especially with
lamotrigine (4 patients with rash; 2 of them with Stevens–Johnson
syndrome). This adverse event was associated with treatment
failure in the lamotrigine group; whereas for valproate, weight-
gain was the most common symptom causing treatment
withdrawal.n the intention-to-treat population.
Number of patients without adverse events Total
22 (30.6) 31 (43.1)
37 (51.4) 41 (56.9)
59 (81.9) 72 (100)
trigine).
Table 3
Clinical and demographic characteristics of randomization groups at study entrance.
Clinical and demographic variables Lamotrigine n = 41 (means  SD [range]) Valproate n = 31 (means  SD [range]))
Age at seizure onset (years) 16.3  6.1 [9–23]) 15.3  7.3 [8–23])
Age at study entrance (years) 26.8  10.9 [15–57] 27.3  12.6 [15–56]
Weight at study entrance (kg) 71.5  13.9 [48–89]) 64.6  12.1[49–86])
Number of tonic-clonic seizures (per month) median [range] 1 [0–10] 2 [0–12]
Number of absences seizures (per month) median [range] 4 [0–60] 2 [0–78]
Number of myoclonic seizures (per month) median [range] 5 [2–60] 6 [3–60]
Time from seizure onset to study entrance (years) 13.9  11.1 12.9  9.1
EEG
Number of patients with generalized polyspikes and spikes and waves 41 (100%) 31 (100%)
photosensitivity + 21 (51.21%) 18 (58.6)
Number of patients with generalized polyspikes and spikes
and waves at the end of the follow-up
2 (4.8%) 0 (0%)
Focal activity + 8 (19.5%) 6 (19.3)
Gender M/F (#/%) 15 (36.6)/26 (63.4) 10 (32.3)/21 (67.4)
Doses employed during follow-up (mg tds) mean SD (range) M/F (ITT) 279  159 (150–400)/249  179 (150–400) 1570  345 (900–3000)/1550  450 (900–2700)
QOLIE-31 (total) 69.5  13.3 62.9  17.85
p values less than 0.05 are marked with *. ITT means intention to treat analysis.
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and 12.3 points in the valproate arm after 2-years of follow-up
(Table 6). All subscales of the QOLIE-31 questionnaire except the
subscale related to side effects of medication improved more than
5 points after treatment. On the other hand, there were signiﬁcant
differences for the outcome assessed by the response rate in
(energy/fatigability, global quality of life, emotional well-being,
cognition functioning) in the valproate group and in emotional
well-being, energy/fatigability in the LTG group (Fig. 3B and C). The
subscale ‘‘side effects of medication’’ worsened in both groups
because the patients had not been taking these drugs at the
starting point and this subscale had been scored as 100. There were
no signiﬁcant differences in the remaining subscales between the
scores at the starting point and at the end of follow-up, between
both study groups.
4. Discussion
Valproate is considered the ﬁrst line antiepileptic drug for
patients with Juvenile Myoclonic Epilepsy (JME). Three other
antiepileptic drugs have been employed (levetiracetam, topir-
amate and zonisamide), which are also said to be effective in
generalized epilepsies.2,5
In developing countries, many of the above mentioned
medications are not part of the therapeutic approach,17–20 because
of their high cost and poor availability; but lamotrigine is available
in our country. Thus, our study constitutes a good example of the
therapeutic scenarios that mirror what happens in other develop-
ing countries.Fig. 2. (A) Cumulative proportion of patients with myoclonic seizures during follow
discontinuous line. Log-Rank Test: WW = 2.141, Sum = 30.4, Var = 7.1. Test statistic = 
follow-up. Valproate has been highlighted with continuous line and lamotrigine with disc
p = 0.85. (C) Cumulative proportion of patients with absence seizures during follow
discontinuous line. Log-Rank Test: WW = 0.51, Sum = 35.2, Var = 8.2. Test statistic = .16Due to the fact that lamotrigine has been associated with
seizure exacerbation in JME,2,21,22,10 the therapeutic alternatives in
developing countries are scarce. In such cases clonazepam
administration in small doses (0.5–2 mg at night) is probably
the most effective treatment for myoclonic jerks; but clonazepam
alone may not suppress GTCS (generalized tonic–clonic sei-
zures).21 Nevertheless, in mild JME with myoclonic jerks only,
clonazepam alone may be recommended.
Thus, physicians prescribe valproate in spite of its well known
teratogenic and cognitive side effects in children exposed in uterus
to this antiepileptic drug.20,23,24 Taking into account that
differences in efﬁcacy among AEDs in newly diagnosed patients
with epilepsy are difﬁcult to detect, according to the review
published by Patrick Kwan and Martin Brodie, we decided to assess
whether treatment with LTG had advantages in tolerability and
safety with respect to valproate; or even if there were no
immediate advantages, if it could be an alternative or second-
line therapy (test of equivalence) for patients with JME.22,10 We
evaluated the effectiveness of LTG as a function of its efﬁcacy and
tolerability as it has been recommended.24–27
In our study we found that the time to withdrawal of
lamotrigine after randomization was not signiﬁcantly higher than
valproate. The long-term seizure freedom was equal in the two
arms of the study: only 8 (19.1%) patients randomized to
lamotrigine and 6 (19.4%) to valproate were not seizure free after
4 months treatment.
When efﬁcacy is similar between two drugs, their overall
effectiveness is often determined by tolerability.24 This is best
measured by the rate of withdrawal of treatment because of
adverse events. Taking this into account, lamotrigine was better-up. Valproate has been highlighted with continuous line and lamotrigine with
2, p = 0.07. (B) Cumulative proportion of patients with tonic–clonic seizures during
ontinuous line. Log-Rank Test: WW = 0.56, Sum = 37.1, Var = 9.2. Test statistic = .18,
-up. Valproate has been highlighted with continuous line and lamotrigine with
, p = 0.75.
Table 4
Number of seizures during follow-up and time from randomization to withdrawal
for any reason and to achieve EEG normalization.
Seizure types Median (range) [IC] (valproate vs. lamotrigine)
Time to withdrawal 11 (3–20) vs. 12 (3–20) [9.2–13.3]; [8.5–16.3]*
Total seizures after
3 months treatment
6 (0–15) [1.2–9.3] vs. 8 (0–60) [1.7–11.3]*
Total seizures after
6 months treatment
1 (0–4) [0.8–2.8] vs. 2 (0–2) [1.1–2.9]*
Total seizures after
24 months treatment
0 (0–3) [0–1.8] vs. 2 (0–4) [1.03–1.4]*
Time to achieve EEG
normalization (weeks)
24 (17–32) vs. 27 (20–38) [21–28.2]; [22–30.1]*,yy
* p > 0.05.
yy Refers to 2 patients (4.8%) that continued with polyspikes and spikes and
waves at the end of the study in the LTG vs. 0 (0%) in the valproate group (per
protocol analysis).
R.A. Machado et al. / Seizure 22 (2013) 846–855852tolerated than valproate (differences between the proportions of
withdrawal rates was signiﬁcantly higher in the valproate group).
Also, the proportion of patients with any adverse event was higher
in the valproate group. We found worsening in myoclonic seizures
in only one (2.4%) of our patients randomized to the LTG arm. This
percentage is very low; nevertheless, it is very important because
of trauma risks associated with myoclonic seizures. Worsening of
seizure rate with lamotrigine has been reported previous-
ly.3,21,22,10
An important concern is the high frequency of Stevens–Johnson
Syndrome found in our study. In the presentation manufacturer’s
product information, the incidence of serious skin rashes, including
Stevens–Johnson syndrome, and rashes requiring hospitalization is
approximately 8 per 1000 in patients younger than 16 years
receiving lamotrigine as adjunctive therapy for epilepsy.28 In
clinical trials of bipolar and other mood disorders, the rate of
serious skin rashes was 0.8 per 1000 in adults receiving
lamotrigine as initial monotherapy and 1.3 per 1000 in adults
receiving lamotrigine as adjunctive therapy. Nevertheless, skin
reactions like maculo-papular erythema were the most frequent,
but less serious side effects found in patients treated with
lamotrigine. Saetre et al. described up to 5% of cutaneous rash
in patients taking lamotrigine for refractory partial epilepsy.29 In
the monograph written by Xiang-ging et al., they described
lamotrigine as the antiepileptic drug that caused the highest
incidence (about 10–12%) of skin reactions.30 In the SANAD study
the authors found 12% of skin reactions in the group of patientsFig. 3. (A) Cumulative proportion of patients with any seizure type during follow-up acc
(Kaplan–Meier curve). Log-Rank Test: WW = 2.01, Sum = 29.4, Var = 5.2.Test statistic =
valproic acid were not seizure free after 4 months treatment. (B) Quality of life at the begi
(before treatment, ﬁrst bars vs. 2 years after treatment, second bars). (1) Total QOLIE, (3) 
cognition functioning, (13) side effects of medication, (15) social functioning. Statistical test
Quality of life at the beginning and after 2 years treatment with lamotrigine. Mean, Mean  S
(1) Total QOLIE, (3) seizure worry, (5) global QOLIE, (7) emotional well-being, (9) energ
functioning. Statistical test: Wilcoxon Matched Pairs Test (*mean p > 0.05,  mean 0.05 
[45.7  20.1 vs. 73.9  15.5; p = 0.000 (t-test)]. Cognitive functioning [valproate vs. lamotrreceiving lamotrigine as monotherapy; moreover the authors did
not mention the number of patients with severe skin reactions or
SJS, and they found that lamotrigine was associated to treatment
failure in 4% of the patients.2 Our results mirror the above
mentioned studies related to rash occurrence and rate of drop out
associated to lamotrigine, but the incidence of SJS was higher. The
main risk factors associated with skin reactions, including SJS, with
lamotrigine treatment are: patient’s age (younger children are
more susceptible than adults), rapid titration schedule and high
initial doses.2,28,31We think that rapid titration schedule played an
important role in the high incidence of SJS in our series. One of the
two patients who presented SJS, increased the total dose to 50 mg
in the third week of follow-up, instead of maintaining a regime of
25 mg daily and the other one increased the total daily dose to
100 mg in the ﬁfth week, instead of continuing with 50 mg/day as
we had proposed. Thus, it could account for the high incidence of
SJS presentation in our study.
A signiﬁcant problem and well-documented side effect linked
to valproate but not to lamotrigine are the weight-gain and the
endocrinologic abnormalities like (polycystic ovary syndrome) and
amenorrhea. In our study 16.1% in the valproate group increased
weight after treatment and 6.4% presented with amenorrhea.
Nevertheless, we did not assess any hormonal or structural ovarian
changes in women taking part in this study, so we cannot comment
on a possible difference in endocrine side effects of the two drugs.
In both treatment groups the overall quality of life improved
signiﬁcantly. Nevertheless, unlike the lamotrigine group, a slighter
improvement in certain domains of quality of life was observed in
patients treated with valproate (cognitive functioning and global
quality of life), and these advantages could be important because
cognitive functioning was worse in the valproate group at the
starting point than in the lamotrigine group. It is important to
explain why the QOLIE-31 score improved more for VPA than LTG;
in spite of the fact that adverse events were 2 fold higher for VPA.
We think that the effect of valproate on emotional feelings could
explain that result partially. Nevertheless, the comparison of
QOLIE-31 between patients under treatment with LTG and
valproate were made in per protocol analysis. Most of the patients
with adverse events were dropped out of the study and the QOLIE-
31 score at the end of the study was not available. In the case of
valproate, nine patients were dropped drop out because of
unacceptable side effects. Maybe this is the main explanation
for the slight improvement in total QOLIE-31 score observed in the
valproate group.ording to group of randomization. Cumulative Proportion of patients with seizures
 1.6, p = 0.09. Eight (19.1%) patients randomized to lamotrigine and 6 (19.4%) to
nning and after 2 years treatment with valproate. Mean, Mean  SD, Mean  1.96*SD
seizure worry, (5) global QOLIE, (7) emotional well-being, (9) energy/fatigability, (11)
: Wilcoxon Matched Pairs Test (*mean p > 0.05, mean 0.05 < p > 0.01, ¥ p < 0.01). (C)
D, Mean  1.96*SD (before treatment, ﬁrst bars vs. 2 years after treatment, second bars).
y/fatigability, (11) cognition functioning, (13) side effects of medication, (15) social
< p > 0.01, ¥p < 0.01). Global quality of life [valproate vs. lamotrigine; Mean  SD]
igine; Mean  SD] [58.8  26.5 vs. 79  11.8; p = 0.01 (t-test)].
Table 5
Drug consumption rate and adverse events during treatment according to
antiepileptic medication.
Consumption rate LTG (%)b Valproate (%)b
Consumption rate around 80% 3 (7.3) 2 (6.5)
Consumption rate between 90% and 100% 38 (92.7) 29 (93.5)
Side effects
Percentage of patients with adverse events 7 (17.03) 11 (35,3)a
Tiredness/drowsiness/fatigue/lethargy 1 (2.4) 2(6.4)
Sleep disturbances 3(7.3) 1(3.2)
Ataxia 0 1(3.2)
Worsening of seizures (myoclonus) 1(2.4) 0
Behavior/personality change/aggression 1(2.4) 1(3.2)
Weight gain 0 5 (16.1)
Dyspepsia 1(2.4) 3 (9.7)
Diarrhea 0 1(3.2)
Abdominal pain 0 2(6.4)
Alopecia 0 3 (9.7)
Anovulatory cycles (amenorrhea) 0 2(6.4)
Subcutaneous edema 0 2(6.4)
Headache 1(2.4) 1(3.2)
Memory problems 0 1(3.2)
Weight loss 1(2.4) 0
Allergic rash 4(9.8)yy 0
Tremor 0 2 (6.4)
Dizziness/vertigo 0 1(3.2)
Anxiety/agitation/nervousness 0 2(6.4)
Nausea 0 9 (29.1)
a Difference of adverse events presentation between drugs: chi squared
test = 1.65; p = 0.03.
b Percentages are referred to the total of patients per group.
yy Symbol is referred to the presentation of Stevens Johnson rash in two patients.
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Methodological biases could explain some of these differences,
since dosing was left to the physician’s usual practice and lower
doses of VPA were used in females. Nevertheless, the doses were
not disproportionately lower for women on VPA. In our study
valproate was given three times a day. This may reduce compliance
and account for the drop-out of some patients. Nevertheless, in this
study this does not seem to be the case, as compliance measured by
the number of pills taken every month was the same in both
groups. On the other hand, patients with poor compliance were not
eligible for the study. We must consider that the slower maximum
dose escalation for LTG may have contributed to a better
tolerability. However, this is the usual dose escalation recom-
mended in other studies,5–20 and reﬂects the dose escalation used
for both medications (valproate and lamotrigine) in our common
clinical practice.
Other possible methodological biases in our study could be
related to selection preference due to the fact that this was an open
label study which only had power to detect a fairly large difference
in efﬁcacy. In spite of the very different sample size enrolled for
LTG and VPA, the randomization process worked as intended. This
was due to patients’ self decision, because some of them did not
pick up their medication after they were randomized. Thus, more
patients randomized to the valproate arm did not initiate theTable 6
Differences among the subscales on the QOLIE-31 questionnaire at entrance and at
the end of study according to groups of randomization.
QOLIE-31 (mean  2.5 SD)/medication Lamotrigine Valproate
Total QOLIE-31 score 7.3 12.3
Seizure worry 10.4 14.3
Emotional well-being 9.3 11.7
Energy/fatigability 12.5 12.5
Cognition functioning 5.3 11.4
Side effects of medication 27.1 35
Social functioning 10.9 8.3recommended treatment. Although we do not know exactly why
this happened, the cause could be related to the adverse effect
proﬁles discussed in their ﬁrst visit, when the patients were
enrolled. Thus, the discrepancy between the sample sizes of the
two treatment arms could have affected the evaluation of safety
and tolerability in our study.
Another methodological concern is how all seizure types were
accurately counted, because it is well known that daily count of
absence and myoclonic seizures could be inaccurate. That is why,
all conclusions taking into account seizure rates, can be mislead-
ing. Nevertheless, our primary ending point was related to the time
to withdraw treatment of any cause and to the time to achieve
remission of all seizure types taking into account the normaliza-
tion of the EEG recording (see Seizure Outcome Assessment in the
Section 2). Thus, this methodological problem could be mitigated.
Another concern is the possible bias associated with the
discontinuation of the medications that patients were taking
before study entrance. This could affect the total count of seizures
per month due to the possible increase in seizure frequency
associated to clonazepam discontinuation or, the possible decrease
in seizure frequency due to withdrawal of phenytoin or
carbamazepine, which are antiepileptic drugs that induce myo-
clonic jerks. The follow-up of the patients for 8 weeks without any
medication to evaluate their actual seizure rate at baseline would
have been required; nevertheless, for ethical reasons it was not
possible.
The unexpectedly low adverse event rates presented in our
study (17% in the LTG arm and 35.5% in the valproate group) is
another issue that should be discussed. We think that this result is
related to how adverse events were deﬁned and how they were
detected/enquired at each visit. In the present study the adverse
events were counted asking the subjects whether they felt any
symptom after drug treatment was initiated. A structured
questionnaire with all well known side effects of valproate and
LTG would improve the detection of potential adverse effects.
However, our method replicates what clinicians do in their
everyday practice. Moreover, we did not assess the possible
structural ovarian and hormonal changes in women taking part in
this study, so we cannot comment on the endocrine side effects of
the two drugs, which could also account for the relatively low rate
of side effects found in our study.
To our knowledge, there are no randomized controlled studies
that have directly compared valproate and lamotrigine mono-
therapy in a JME adult population. Therefore, we have no reliable
evidence about the relative effectiveness of lamotrigine for taking
clinical decisions in adults, especially for women of childbearing
potential. The SANAD (Standard and New Antiepileptic Drug) study
deserves a special mention. This study directly compared
lamotrigine, topiramate and valproate in a well designed
pragmatic, controlled, randomized, prospective study.2 Neverthe-
less, none of the comparative analyses were carried out taking into
account the different subtypes of IGE and it also included
unclassiﬁed types of IGE syndromes. These aspects could
differentiate our study from SANAD. For example, Jeavons
Syndrome, one of the non-classiﬁed IGE syndromes, should be
considered a myoclonic rather than an absence epilepsy, and this
concept has therapeutic consequences, supporting the good
clinical efﬁcacy of antimyoclonic drugs such as levetiracetam
and zonisamide25 and some patients have also been reported to
show resistance to lamotrigine therapy.26,32 The above study also
included persons of all ages.2,25 Age could be an important factor
for treatment response in IGE and patients with a longer time to
diagnosis had a good response to LTG.32–34 Nearly one-third of
their patients with delayed diagnosis were initially treated with
AEDs that were inappropriate for JME, including carbamazepine
and phenytoin and they achieved a good response after changing to
R.A. Machado et al. / Seizure 22 (2013) 846–855854LTG. As for the other patients, the delay in their diagnosis may be
related to a benign clinical presentation, although the combination
of seizure types was similar in patients with or without delayed
diagnosis.35 These variables could have played a role in our study,
too.
One of the most important biases of our study could be that it
was conducted by physicians in a tertiary center. Nevertheless,
none of our patients was refractory to antiepileptic drugs, the
electroclinical characteristics were typical of JME, the men/female
ratio was similar to other studies35–37 and the population in our
tertiary center is not different from that of secondary or primary
centers, because of the organization of health care in Cuba. For that
reason, our study mainly reﬂects community based studies.
Another important concern is the power of the sample size
calculation. In line with the objective of the more recent studies,
our study is dedicated to demonstrate equivalence between
lamotrigine and valproate. The design of equivalence trials differs
from that of the traditional studies, aiming to detect differences in
many important aspects. Fundamentally, instead of the conven-
tional test for signiﬁcance, statistical analysis is based on
conﬁdence intervals (CIs) that deﬁne a range for the possible true
difference between the drugs.1,38 Taking this paradigm into
account, the two drugs under study can be regarded as equivalent
if the entire CI for their difference lies within the pre-set clinically
relevant range of equivalence. In our study we did not ﬁnd
differences between lamotrigine and valproate, considering CI for
different primary end points (time to reach 50% of seizure control,
time to withdrawal for any cause and time to achieve remission
according to group of randomization). That is why, although we did
not analyze the power of sample size calculation, this concern is
mitigated by the objective of our investigation.
One of the most important cautions in prescribing lamotrigine
in JME is the probability of myoclonic seizure worsening. This
exacerbation in seizure rate, especially for myoclonic seizures, was
reported by Fernando-Dongas et al.39 and Biraben et al.3 The later
authors reported seven patients with myoclonus exacerbated by
treatment with lamotrigine (LTG), four of whom were taking LTG
monotherapy. This observation and our present results, where 1
(2.4%) of the patients experienced worsening of his seizure rate,
raise concerns about the rationale of using LTG in the treatment of
JME.
Because of possible hair loss, weight gain, and menstrual
irregularities with valproate treatment, many physicians have
used LTG as a ﬁrst-line therapy in women with JME. Our positive
experience with the drug contrasts with that reported by Biraben
et al.3 and slightly reﬂects the retrospective study of 24 patients
with an established diagnosis of JME conducted by Carrazana
et al.10 In the Carrazana study seizure control was excellent
(seizure freedom), although two of the 24 patients developed a
dramatic exacerbation of myoclonus, leading to LTG therapy
discontinuation.37 An additional two patients had a mild increase
in morning myoclonus, but it was transient, and sporadic GTCS
continued in 2/24 patients (8.3%). In one patient, the occurrence of
sporadic seizures was attributed to poor therapy compliance.
Other investigators have reported similar positive experiences
with the use of LTG for JME treatment.40 The differences in the
reported experience with LTG in JME may be due to a recruitment
bias.
We agree that further studies are needed to establish the degree
of efﬁcacy and tolerability of LTG in the treatment of JME patients.
We believe that, in the light of certain side effects of VPA treatment
in female patients, LTG should be considered as an alternative
option. Our experience suggests that exacerbation of myoclonus is
seen in a small number of patients.
This observation is not in contradiction with the reports of a
possible exacerbation of myoclonic seizures caused by LTG,because JME is most certainly a heterogeneous entity.41,42 Keeping
this variability in mind and owing to the fact that no simple test has
been developed to identify these patients, we believe it is most
important to emphasize the need for utmost prudence when using
LTG in patients with JME.
4.2. Conclusion
According to ours results, lamotrigine is effective in adult
patients with Juvenile Myoclonic Epilepsy and better tolerated
than valproate. Thus, lamotrigine could be a treatment alternative
for women with JME in developing countries, although the
incidence of idiosyncratic reactions could be a concern.
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